Sudanese RVF (rift valley fever) crisis worsens, adding to diagnostic challenge:
This article was originally published in Clinica
Executive Summary
The number of cases of rift valley fever (RVF) in Sudan has increased rapidly since outbreaks were first detected in late October, now posing further diagnostic surveillance challenges. By November 14, 329 cases and 96 deaths had been recorded across the states of Gazeera, West Nile, Sinnar and Khartoum, according to the WHO. There has, however, been no update on the results of confirmatory testing said to rely on PCR (polymerase chain reaction) and ELISA (enzyme-linked immuno-sorbent assay) laboratory support. By November 7, 25 positives had been confirmed using these; three cases in Khartoum were then confirmed as negative, though new "imported" cases are being reported. Laboratory support is being provided primarily by the Cairo, Egypt-based WHO collaborating centre for emerging infectious diseases, NAMRU-3.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.